Nutriband Inc. (NTRB)
Oxford Ledge is still expanding full research coverage of NTRB. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Nutriband develops abuse-deterrent transdermal pharmaceutical products through its AVERSA technology and operates contract manufacturing and research subsidiaries.
SEC filings
- 8-K Entry into material agreement; Financial statements and exhibits 2026-06-22
- 10-Q Quarterly financial report (unaudited) 2026-06-11
- 10-K/A Amended annual report 2026-05-18
- 10-K Annual financial report with audited statements 2026-04-29
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-04-07
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NTRB. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NTRB in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.